Literature DB >> 16242467

Pulmonary resection for metastatic malignant fibrous histiocytoma: an analysis of prognostic factors.

Rakesh M Suri1, Claude Deschamps, Stephen D Cassivi, Francis C Nichols, Mark S Allen, Cathy D Schleck, Peter C Pairolero.   

Abstract

BACKGROUND: Factors affecting recurrence and survival after pulmonary resection for metastatic malignant fibrous histiocytoma (MFH) are not well known.
METHODS: Records of patients undergoing pulmonary metastasectomy for MFH between January 1976 and January 2000 were analyzed.
RESULTS: There were 103 patients (46 men and 57 women). Median age was 60 years (range, 20 to 86). Malignant fibrous histiocytoma metastasis was solitary in 29 patients (28%), multiple/unilateral in 33 (32%), and multiple/bilateral in 41 (40%). Median time interval from primary tumor resection to metastasectomy was 11 months (range, 0 to 86). Wedge resection was carried out in 87 patients (84%), segmentectomy in 3 (3%), lobectomy in 3 (3%), pneumonectomy in 2 (2%), and a combination of resections in 8 (8%). Resection was complete in 93 patients (90%). Complications occurred in 11 patients (11%) and included prolonged air leak in 7, and pneumonia, empyema, atelectasis, and sepsis in 1 each. One patient died (operative mortality, 1%). Follow-up ranged from 2 weeks to 153 months (median, 18 months). Five-year survival was 21% (95% confidence interval, 14% to 31%). In the 103 patients, incomplete resection (p < 0.0001) was associated with decreased survival. Among the 93 patients with complete resection, factors associated with decreased survival included the presence of extrapulmonary disease at time of metastasectomy (p = 0.01), more than two nodules resected (p = 0.001), and adjuvant therapy after metastasectomy (p = 0.0007).
CONCLUSIONS: Pulmonary resection of metastatic MFH is safe. Improved survival was associated with the absence of extrapulmonary disease at time of metastasectomy, with fewer than three pulmonary nodules resected, and with a complete resection.

Entities:  

Mesh:

Year:  2005        PMID: 16242467     DOI: 10.1016/j.athoracsur.2005.05.004

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

Review 1.  The role of local therapy in the management of lung and liver oligometastases.

Authors:  Simon S Lo; Susan D Moffatt-Bruce; Laura A Dawson; Roderich E Schwarz; Bin S Teh; Nina A Mayr; Jiade J Lu; John C Grecula; Thomas E Olencki; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2011-05-24       Impact factor: 66.675

Review 2.  Survival and prognostic factors following pulmonary metastasectomy for sarcoma.

Authors:  Giuseppe Marulli; Marco Mammana; Giovanni Comacchio; Federico Rea
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas.

Authors:  Hiroshi Urakawa; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2016-09-07       Impact factor: 5.150

Review 4.  Oligometastasis and oligo-recurrence: more than a mirage.

Authors:  Fang Huang; Gang Wu; Kunyu Yang
Journal:  Radiat Oncol       Date:  2014-10-31       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.